Teladoc Health Relocates Principal Executive Offices

TL;DR

TDOC moved its HQ to Purchase, NY effective Oct 30, 2024.

AI Summary

On October 30, 2024, Teladoc Health, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2 Manhattanville Road, Suite 203, Purchase, NY 10577. This move is effective as of October 30, 2024.

Why It Matters

A change in principal executive offices can signal operational shifts or strategic realignments within a company. Investors should monitor if this move impacts operational efficiency or costs.

Risk Assessment

Risk Level: low — This filing primarily concerns a change of address for the company's principal executive offices, which typically carries low risk.

Key Players & Entities

• Teladoc Health, Inc. (company) — Registrant
• 2 Manhattanville Road, Suite 203, Purchase, NY 10577 (location) — New Principal Executive Offices
• October 30, 2024 (date) — Effective date of address change

FAQ

From the Filing

0001477449-24-000224.txt : 20241030 0001477449-24-000224.hdr.sgml : 20241030 20241030161134 ACCESSION NUMBER: 0001477449-24-000224 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241030 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241030 DATE AS OF CHANGE: 20241030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 241410436 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 8-K 1 tdoc-20241030.htm 8-K tdoc-20241030 FALSE 0001477449 0001477449 2023-07-25 2023-07-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 8-K ___________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 30, 2024 ___________________________________ Teladoc Health, Inc. (Exact name of registrant as specified in its charter) ___________________________________ Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3705970 (I.R.S. Employer Identification No.) 2 Manhattanville Road Suite 203 Purchase , NY 10577 (Address of principal executive offices and zip code) ( 203 ) 635-2002 (Registrant's telephone number, including area code) ___________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.001 per share TDOC The New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02.    Results of Operations and Financial Condition. On October 30, 2024, Teladoc Health, Inc. (the “Company”) issued a press release relating to its financial results for the third quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by refere